Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
echium amoenum + rheum ribes is an investigational herbal combination therapy formulated as an oral syrup for the treatment of obsessive-compulsive disorder (OCD). The combination consists of extracts from *Echium amoenum* L. (commonly known as Iranian Borage) and *Rheum ribes* (Syrian Rhubarb). In clinical evaluations, specifically a triple-blind, randomized, controlled trial (IRCT20200712048088N1), the syrup demonstrated efficacy in reducing the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) over an 8-week period. While the exact mechanism of action is not fully defined, the therapeutic effects are thought to be mediated by the synergistic action of phytochemicals—such as flavonoids and rosmarinic acid—on central nervous system pathways, potentially involving serotonergic modulation. The treatment has been reported as safe with no significant adverse effects compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echium amoenum + rheum ribes.